At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 284 enrolled
Drug / intervention
JNS001 +1 moredrug
Likely dose
JNS001 18 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 36 mg, 54 mg, or 72 mg Per Day
In Brief
A Phase 3 clinical trial evaluating JNS001 and Placebo for Attention-Deficit Hyperactivity Disorder. Completed, enrolled 284 participants across 30 sites.
Detailed Summary
The main purpose of this study is to evaluate the efficacy of JNS001 titrated to daily doses of 18 to 72 mg in adults with attention-deficit hyperactivity disorder (ADHD) relative to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention-Deficit Hyperactivity Disorder
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedMar 2011
Primary CompletionApr 2012
TodayJul 2026
First PostedMar 25, 2011
Enrollment StartMar 1, 2011
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.3 years ago
Interventions
JNS001drug
Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
Placebodrug
Participants will receive matching placebo orally once daily for 8 weeks.